CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2021 at "Oncoimmunology"
DOI: 10.1080/2162402x.2021.2000699
Abstract: ABSTRACT Multiple myeloma (MM) is a hematological malignancy characterized by the presence of clonal plasma cells in the bone marrow niche. Despite significant therapeutic advances, MM remains incurable for the majority of patients. Targeted radionuclide… read more here.
Keywords: expression; actinium 225; cs1; single domain ... See more keywords
Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0261982
Abstract: Hepatocellular carcinoma is the most common primary liver cancer and the fifth most frequently diagnosed cancer worldwide. Most patients with advanced disease are offered non-surgical palliative treatment options. This work explores the first alpha-particle emitting… read more here.
Keywords: hepatocellular carcinoma; spect imaging; emitting radioembolization; agent ... See more keywords
Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2022.1030094
Abstract: Osteosarcoma is a high-grade sarcoma characterized by osteoid formation, nearly universal expression of IGF1R and with a subset expressing HER-2. These qualities provide opportunities for the use of the alpha particle-emitting isotopes to provide targeted… read more here.
Keywords: thorium 227; particle; targeted alpha; alpha particle ... See more keywords